Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Allan Wailoo

Showing results (1-10 of 64) with videos related to

Pageof 7
Sort By:
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
Using health state utility values in models exploring the cost-effectiveness of health technologiesRoberta Ara, Allan Wailoo
Health and Quality of Life Outcomes|February 20, 2013
A review of the psychometric performance of the EQ-5D in people with urinary incontinenceSarah Davis, Allan Wailoo
Social Science & Medicine (1982)|November 4, 2004
The nature of procedural preferences for health-care rationing decisionsAllan Wailoo, Paul Anand
Lancet (London, England)|September 19, 2003
NICE's citizen's council: what do we ask them, and how?Paul Dolan, Aki Tsuchiya, Allan Wailoo
BMC Health Services Research|August 15, 2008
Cost effectiveness of chest pain unit care in the NHSYemi Oluboyede, Steve Goodacre, Allan Wailoo, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 23, 2014
Societal preferences for distributive justice in the allocation of health care resources: a latent class discrete choice experimentChris Skedgel, Allan Wailoo, Ron Akehurst
Pharmacoeconomics|November 14, 2009
Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expectedAllan Wailoo, Aki Tsuchiya, Christopher McCabe
Rheumatology (Oxford, England)|January 23, 2008
Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidanceAllan Wailoo, Nick Bansback, Jim Chilcott
Pharmacoeconomics|November 30, 2022
Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population StudyMónica Hernández Alava, Steve Pudney, Allan Wailoo
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 12, 2020
The EQ-5D-5L Value Set for England: Findings of a Quality Assurance ProgramMonica Hernandez Alava, Stephen Pudney, Allan Wailoo
Pageof 7

Showing results (1-10 of 64) with videos related to

Sort By:
Pageof 7
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|September 25, 2012
Using health state utility values in models exploring the cost-effectiveness of health technologiesRoberta Ara, Allan Wailoo
Health and Quality of Life Outcomes|February 20, 2013
A review of the psychometric performance of the EQ-5D in people with urinary incontinenceSarah Davis, Allan Wailoo
Social Science & Medicine (1982)|November 4, 2004
The nature of procedural preferences for health-care rationing decisionsAllan Wailoo, Paul Anand
Lancet (London, England)|September 19, 2003
NICE's citizen's council: what do we ask them, and how?Paul Dolan, Aki Tsuchiya, Allan Wailoo
BMC Health Services Research|August 15, 2008
Cost effectiveness of chest pain unit care in the NHSYemi Oluboyede, Steve Goodacre, Allan Wailoo, et al.
Medical Decision Making : an International Journal of the Society for Medical Decision Making|August 23, 2014
Societal preferences for distributive justice in the allocation of health care resources: a latent class discrete choice experimentChris Skedgel, Allan Wailoo, Ron Akehurst
Pharmacoeconomics|November 14, 2009
Weighting must wait: incorporating equity concerns into cost-effectiveness analysis may take longer than expectedAllan Wailoo, Aki Tsuchiya, Christopher McCabe
Rheumatology (Oxford, England)|January 23, 2008
Infliximab, etanercept and adalimumab for the treatment of ankylosing spondylitis: cost-effectiveness evidence and NICE guidanceAllan Wailoo, Nick Bansback, Jim Chilcott
Pharmacoeconomics|November 30, 2022
Estimating the Relationship Between EQ-5D-5L and EQ-5D-3L: Results from a UK Population StudyMónica Hernández Alava, Steve Pudney, Allan Wailoo
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|May 12, 2020
The EQ-5D-5L Value Set for England: Findings of a Quality Assurance ProgramMonica Hernandez Alava, Stephen Pudney, Allan Wailoo
Pageof 7